The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Immune boosting by B.1.1.529 ( Omicron) depends on previous SARS-CoV-2 exposure
Open accessAbstract
The Omicron, or Pango lineage B.1.1.529, variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) carries multiple spike mutations with high transmissibility and partial neutralizing antibody (nAb) escape. Vaccinated individuals show protection against severe disease, often attributed to primed cellular immunity. We investigated T and B cell immunity against B.1.1.529 in triple BioNTech BNT162b2 messenger RNA–vaccinated health care workers (HCWs) with different SARS-CoV-2 infection histories. B and T cell immunity against previous variants of concern was enhanced in triple-vaccinated individuals, but the magnitude of T and B cell responses against B.1.1.529 spike protein was reduced. Immune imprinting by infection with the earlier B.1.1.7 (Alpha) variant resulted in less durable binding antibody against B.1.1.529. Previously infection-naïve HCWs who became infected during the B.1.1.529 wave showed enhanced immunity against earlier variants but reduced nAb potency and T cell responses against B.1.1.529 itself. Previous Wuhan Hu-1 infection abrogated T cell recognition and any enhanced cross-reactive neutralizing immunity on infection with B.1.1.529.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern
Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., O’Connell, A.-M., et al. (2021) · doi:10.1101/2021.12.14.21267615 · Cited by 2,420
Reynisson, B., Alvarez, B., Paul, S., Peters, B., & Nielsen, M. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa379 · Cited by 2,361
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
Planas, D., Saunders, N., Maes, P., Guivel-Benhassine, F., Planchais, C., Buchrieser, J., Bolland, W.-H., Porrot, F., Staropoli, I., Lemoine, F., et al. (2022) · Nature · doi:10.1038/s41586-021-04389-z · Cited by 1,514
Cele, S., Jackson, L., Khoury, D. S., Khan, K., Moyo-Gwete, T., Tegally, H., San, J. E., Cromer, D., Scheepers, C., Amoako, D., et al. (2021) · doi:10.1101/2021.12.08.21267417 · Cited by 1,333
Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
Liu, L., Iketani, S., Guo, Y., Chan, J. F.-W., Wang, M., Liu, L., Luo, Y., Chu, H., Huang, Y., Nair, M. S., et al. (2022) · Nature · doi:10.1038/s41586-021-04388-0 · Cited by 1,290
Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic
Karim, S. S. A., & Karim, Q. A. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02758-6 · Cited by 1,226
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
McCallum, M., De Marco, A., Lempp, F. A., Tortorici, M. A., Pinto, D., Walls, A. C., Beltramello, M., Chen, A., Liu, Z., Zatta, F., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.028 · Cited by 901 · cited 1×
“that antibody targeting regions outside RBD and/or spike or conformational epitopes exposed only during infection may contribute to neutralization (26, 27) (Fig.”
Tarke, A., Coelho, C. H., Zhang, Z., Dan, J. M., Yu, E. D., Methot, N., Bloom, N. I., Goodwin, B., Phillips, E., Mallal, S., et al. (2022) · Cell · doi:10.1016/j.cell.2022.01.015 · Cited by 858
SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo
Hui, K. P. Y., Ho, J. C. W., Cheung, M.-C., Ng, K.-C., Ching, R. H. H., Lai, K.-L., Kam, T. T., Gu, H., Sit, K.-Y., Hsin, M. K. Y., et al. (2022) · Nature · doi:10.1038/s41586-022-04479-6 · Cited by 836
T cell responses to SARS-CoV-2 spike cross-recognize Omicron
Keeton, R., Tincho, M. B., Ngomti, A., Baguma, R., Benede, N., Suzuki, A., Khan, K., Cele, S., Bernstein, M., Karim, F., et al. (2022) · Nature · doi:10.1038/s41586-022-04460-3 · Cited by 633
Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
Collie, S., Champion, J., Moultrie, H., Bekker, L.-G., & Gray, G. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119270 · Cited by 600
Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants
Tseng, H. F., Ackerson, B. K., Luo, Y., Sy, L. S., Talarico, C. A., Tian, Y., Bruxvoort, K. J., Tubert, J. E., Florea, A., Ku, J. H., et al. (2022) · doi:10.1101/2022.01.07.22268919 · Cited by 541
Cerutti, G., Guo, Y., Zhou, T., Gorman, J., Lee, M., Rapp, M., Reddem, E. R., Yu, J., Bahna, F., Bimela, J., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.03.005 · Cited by 519
Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron
Liu, J., Chandrashekar, A., Sellers, D., Barrett, J., Jacob-Dolan, C., Lifton, M., McMahan, K., Sciacca, M., VanWyk, H., Wu, C., et al. (2022) · Nature · doi:10.1038/s41586-022-04465-y · Cited by 451
Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant
Gao, Y., Cai, C., Grifoni, A., Müller, T. R., Niessl, J., Olofsson, A., Humbert, M., Hansson, L., Österborg, A., Bergman, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01700-x · Cited by 403
Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
Manisty, C., Otter, A. D., Treibel, T. A., McKnight, Á., Altmann, D. M., Brooks, T., Noursadeghi, M., Boyton, R. J., Semper, A., & Moon, J. C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00501-8 · Cited by 369
Self-citationNeutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera
Muik, A., Lui, B. G., Wallisch, A.-K., Bacher, M., Mühl, J., Reinholz, J., Ozhelvaci, O., Beckmann, N., Güimil Garcia, R. D. L. C., Poran, A., et al. (2022) · Science · doi:10.1126/science.abn7591 · Cited by 367
Population Immunity and Covid-19 Severity with Omicron Variant in South Africa
Madhi, S. A., Kwatra, G., Myers, J. E., Jassat, W., Dhar, N., Mukendi, C. K., Nana, A. J., Blumberg, L., Welch, R., Ngorima-Mabhena, N., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2119658 · Cited by 366
Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose
Reynolds, C. J., Pade, C., Gibbons, J. M., Butler, D. K., Otter, A. D., Menacho, K., Fontana, M., Smit, A., Sackville-West, J. E., Cutino-Moguel, T., et al. (2021) · Science · doi:10.1126/science.abh1282 · Cited by 338
Self-citationCOVID-19: PCR screening of asymptomatic health-care workers at London hospital
Treibel, T. A., Manisty, C., Burton, M., McKnight, Á., Lambourne, J., Augusto, J. B., Couto-Parada, X., Cutino-Moguel, T., Noursadeghi, M., & Moon, J. C. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31100-4 · Cited by 314
Self-citationT cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals
Naranbhai, V., Nathan, A., Kaseke, C., Berrios, C., Khatri, A., Choi, S., Getz, M. A., Tano-Menka, R., Ofoman, O., Gayton, A., et al. (2022) · Cell · doi:10.1016/j.cell.2022.01.029 · Cited by 244
Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine
Goel, R. R., Painter, M. M., Lundgreen, K. A., Apostolidis, S. A., Baxter, A. E., Giles, J. R., Mathew, D., Pattekar, A., Reynaldi, A., Khoury, D. S., et al. (2022) · Cell · doi:10.1016/j.cell.2022.04.009 · Cited by 207
Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection
Reynolds, C. J., Swadling, L., Gibbons, J. M., Pade, C., Jensen, M. P., Diniz, M. O., Schmidt, N. M., Butler, D. K., Amin, O. E., Bailey, S. N. L., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abf3698 · Cited by 200
Self-citationGagne, M., Moliva, J. I., Foulds, K. E., Andrew, S. F., Flynn, B. J., Werner, A. P., Wagner, D. A., Teng, I.-T., Lin, B. C., Moore, C., et al. (2022) · Cell · doi:10.1016/j.cell.2022.03.038 · Cited by 200
Beyond Omicron: what’s next for COVID’s viral evolution
Callaway, E. (2021) · Nature · doi:10.1038/d41586-021-03619-8 · Cited by 190
Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2
Israelow, B., Mao, T., Klein, J., Song, E., Menasche, B., Omer, S. B., & Iwasaki, A. (2021) · Science Immunology · doi:10.1126/sciimmunol.abl4509 · Cited by 189
Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2
Israelow, B., Mao, T., Klein, J., Song, E., Menasche, B., Omer, S. B., & Iwasaki, A. (2021) · doi:10.1101/2021.05.19.444825 · Cited by 189
Milder disease with Omicron: is it the virus or the pre-existing immunity?
Sigal, A. (2022) · Nature reviews. Immunology · doi:10.1038/s41577-022-00678-4 · Cited by 141
Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants
Reynolds, C. J., Gibbons, J. M., Pade, C., Lin, K., Sandoval, D. M., Pieper, F. P., Butler, D. K., Liu, S., Otter, A. D., Joy, G., et al. (2022) · Science · doi:10.1126/science.abm0811 · Cited by 140
Self-citationRapid increase in Omicron infections in England during December 2021: REACT-1 study
Elliott, P., Bodinier, B., Eales, O. D., Wang, H., Haw, D., Elliott, J., Whitaker, M. D., Jonnerby, J., Tang, D. G., Walters, C. E., et al. (2022) · Science · doi:10.1126/science.abn8347 · Cited by 130
Richardson, S. I., Madzorera, V. S., Spencer, H., Manamela, N. P., van der Mescht, M. A., Lambson, B. E., Oosthuysen, B., Ayres, F., Makhado, Z., Moyo-Gwete, T., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.03.029 · Cited by 119
Neutralization Profile after Recovery from SARS-CoV-2 Omicron Infection
Rössler, A., Knabl, L., von Laer, D., & Kimpel, J. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2201607 · Cited by 95
Parker, R., Partridge, T., Wormald, C., Kawahara, R., Stalls, V., Aggelakopoulou, M., Parker, J., Doherty, R. P., Ariosa-Morejon, Y., Lee, E., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109179 · Cited by 78
Self-citationManisty, C., Treibel, T. A., Jensen, M. P., Semper, A. E., Joy, G., Gupta, R. K., Cutiño‐Moguel, T., Andiapen, M., Jones, J., Taylor, S. C., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103259 · Cited by 63
Self-citationThe Human Leukocyte Antigen Class II Immunopeptidome of the SARS-CoV-2 Spike Glycoprotein
Knierman, M. D., Lannan, M. B., Spindler, L. J., McMillian, C. L., Konrad, R. J., & Siegel, R. W. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108454 · Cited by 49
Reynolds, C. J., Goudet, A., Jenjaroen, K., Sumonwiriya, M., Rinchai, D., Musson, J. A., Overbeek, S. A., Makinde, J., Quigley, K. J., Manji, J., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402862 · Cited by 37
Self-citationQuigley, K. J., Reynolds, C. J., Goudet, A., Raynsford, E. J., Sergeant, R., Quigley, A., Worgall, S., Bilton, D., Wilson, R., Loebinger, M. R., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201411-1995oc · Cited by 33
Self-citation
Cited by
Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution
Cao, Y., Jian, F., Wang, J., Yu, Y., Song, W., Yisimayi, A., Wang, J., An, R., Chen, X., Zhang, N., et al. (2023) · Nature · doi:10.1038/s41586-022-05644-7 · Cited by 841
Shrestha, L. B., Foster, C., Rawlinson, W., Tedla, N., & Bull, R. A. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2381 · Cited by 474
Repeated Omicron exposures override ancestral SARS-CoV-2 immune imprinting
Yisimayi, A., Song, W., Wang, J., Jian, F., Yu, Y., Chen, X., Xu, Y., Yang, S., Niu, X., Xiao, T., et al. (2024) · Nature · doi:10.1038/s41586-023-06753-7 · Cited by 253
In search of a pan-coronavirus vaccine: next-generation vaccine design and immune mechanisms
Cankat, S., Demael, M. U., & Swadling, L. (2023) · Cellular & Molecular Immunology · doi:10.1038/s41423-023-01116-8 · Cited by 84
Wang, W., Lusvarghi, S., Subramanian, R., Epsi, N. J., Wang, R., Goguet, E., Fries, A. C., Echegaray, F., Vassell, R., Coggins, S., et al. (2022) · doi:10.1101/2022.07.05.498883 · Cited by 68
Self-citation
Metadata
- Authors
- Reynolds, C. J., Pade, C., Gibbons, J. M., Otter, A. D., Lin, K.-M., Muñoz Sandoval, D., Pieper, F. P., Butler, D. K., Liu, S., Joy, G., Forooghi, N., Treibel, T. A., Manisty, C., Moon, J. C., COVIDsortium Investigators§, COVIDsortium Immune Correlates Network§, Semper, A., Brooks, T., McKnight, Á., Altmann, D. M., Boyton, R. J., Abbass, H., Abiodun, A., Alfarih, M., Alldis, Z., Altmann, D. M., Amin, O. E., Andiapen, M., Artico, J., Augusto, J. B., Baca, G. L., Bailey, S. N. L., Bhuva, A. N., Boulter, A., Bowles, R., Boyton, R. J., Bracken, O. V., O’Brien, B., Brooks, T., Bullock, N., Butler, D. K., Captur, G., Carr, O., Champion, N., Chan, C., Chandran, A., Coleman, T., Couto de Sousa, J., Couto-Parada, X., Cross, E., Cutino-Moguel, T., D’Arcangelo, S., Davies, R. H., Douglas, B., Di Genova, C., Dieobi-Anene, K., Diniz, M. O., Ellis, A., Feehan, K., Finlay, M., Fontana, M., Forooghi, N., Francis, S., Gibbons, J. M., Gillespie, D., Gilroy, D., Hamblin, M., Harker, G., Hemingway, G., Hewson, J., Heywood, W., Hickling, L. M., Hicks, B., Hingorani, A. D., Howes, L., Itua, I., Jardim, V., Lee, W.-Y. J., Jensen, M., Jones, J., Jones, M., Joy, G., Kapil, V., Kelly, C., Kurdi, H., Lambourne, J., Lin, K.-M., Liu, S., Lloyd, A., Louth, S., Maini, M. K., Mandadapu, V., Manisty, C., McKnight, Á., Menacho, K., Mfuko, C., Mills, K., Millward, S., Mitchelmore, O., Moon, C., Moon, J., Muñoz Sandoval, D., Murray, S. M., Noursadeghi, M., Otter, A., Pade, C., Palma, S., Parker, R., Patel, K., Pawarova, M., Petersen, S. E., Piniera, B., Pieper, F. P., Rannigan, L., Rapala, A., Reynolds, C. J., Richards, A., Robathan, M., Rosenheim, J., Rowe, C., Royds, M., Sackville West, J., Sambile, G., Schmidt, N. M., Selman, H., Semper, A., Seraphim, A., Simion, M., Smit, A., Sugimoto, M., Swadling, L., Taylor, S., Temperton, N., Thomas, S., Thornton, G. D., Treibel, T. A., Tucker, A., Varghese, A., Veerapen, J., Vijayakumar, M., Warner, T., Welch, S., White, H., Wodehouse, T., Wynne, L., Zahedi, D., Chain, B., & Moon, J. C.
- Venue
- Science
- Published
- 2022-07-15
- Volume
- 377
- Issue
- 6603
- Pages
- eabq1841-eabq1841
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W4282838915
- Cited by
- 337
- References
- 37
- FWCI
- 35.04
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.